ATG Plus Cyclophosphamide To Prevent GVHD
A Randomized Pilot Trial Comparing Anti-Thymocyte Globulin (ATG) With ATG Plus Post Transplant Cyclophosphamide (PTCy) for Prophylaxis Against Acute and Chronic Graft Versus Host Disease (GVHD)
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 2
- Enrollment
- 80 patients (estimated)
- Sponsors
- McMaster University
- Collaborators
- Sanofi, Ozmosis Research Inc., Cell Therapy Transplant Canada
- Tags
- Allogeneic Stem Cell Transplant, Post-Allogeneic Stem Cell Transplant, Randomization
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1918
- NCT Identifier
- NCT04202835
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.